RU2015144149A - Протеомные маркеры илф - Google Patents
Протеомные маркеры илф Download PDFInfo
- Publication number
- RU2015144149A RU2015144149A RU2015144149A RU2015144149A RU2015144149A RU 2015144149 A RU2015144149 A RU 2015144149A RU 2015144149 A RU2015144149 A RU 2015144149A RU 2015144149 A RU2015144149 A RU 2015144149A RU 2015144149 A RU2015144149 A RU 2015144149A
- Authority
- RU
- Russia
- Prior art keywords
- fibrotic
- level
- disease
- expression
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 claims 68
- 230000003176 fibrotic effect Effects 0.000 claims 58
- 108090000623 proteins and genes Proteins 0.000 claims 45
- 102000004169 proteins and genes Human genes 0.000 claims 43
- 239000003550 marker Substances 0.000 claims 35
- 208000019693 Lung disease Diseases 0.000 claims 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 29
- 201000010099 disease Diseases 0.000 claims 28
- 230000002685 pulmonary effect Effects 0.000 claims 18
- 239000012472 biological sample Substances 0.000 claims 15
- 210000004072 lung Anatomy 0.000 claims 11
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 8
- 230000000750 progressive effect Effects 0.000 claims 8
- 239000000556 agonist Substances 0.000 claims 7
- 108091023037 Aptamer Proteins 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 150000003384 small molecules Chemical class 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000003172 expectorant agent Substances 0.000 claims 3
- 229940066491 mucolytics Drugs 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- -1 antibody Proteins 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 102000007469 Actins Human genes 0.000 claims 1
- 108010085238 Actins Proteins 0.000 claims 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 1
- 229940076372 protein antagonist Drugs 0.000 claims 1
- 229940076155 protein modulator Drugs 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801476P | 2013-03-15 | 2013-03-15 | |
| US201361801290P | 2013-03-15 | 2013-03-15 | |
| US61/801,476 | 2013-03-15 | ||
| US61/801,290 | 2013-03-15 | ||
| US201361874947P | 2013-09-06 | 2013-09-06 | |
| US61/874,947 | 2013-09-06 | ||
| PCT/US2014/029392 WO2014144821A1 (en) | 2013-03-15 | 2014-03-14 | Proteomic ipf markers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015144149A true RU2015144149A (ru) | 2017-04-21 |
Family
ID=51537804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015144149A RU2015144149A (ru) | 2013-03-15 | 2014-03-14 | Протеомные маркеры илф |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9726677B2 (https=) |
| EP (1) | EP2972392A4 (https=) |
| JP (1) | JP2016519763A (https=) |
| KR (1) | KR20150130408A (https=) |
| CN (1) | CN105122068A (https=) |
| BR (1) | BR112015023699A2 (https=) |
| CA (1) | CA2901384A1 (https=) |
| HK (1) | HK1219533A1 (https=) |
| MX (1) | MX2015012778A (https=) |
| RU (1) | RU2015144149A (https=) |
| WO (1) | WO2014144821A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US8669057B2 (en) | 2009-05-07 | 2014-03-11 | Veracyte, Inc. | Methods and compositions for diagnosis of thyroid conditions |
| RU2015144149A (ru) | 2013-03-15 | 2017-04-21 | Интермьюн, Инк. | Протеомные маркеры илф |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| EP3215170A4 (en) | 2014-11-05 | 2018-04-25 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| WO2018191751A1 (en) * | 2017-04-14 | 2018-10-18 | Arizona Board Of Regents On Behalf Of The University Of Arizonia | Compositions and methods for treating pulmonary fibrosis |
| US10975167B2 (en) | 2017-04-14 | 2021-04-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method to reduce pulmonary arterial hypertension by administering inhibitors of nicotinamide phosphoribotransferase |
| CN107677835B (zh) * | 2017-09-26 | 2019-08-09 | 上海市肺科医院 | 一种ae-ipf的蛋白标记物及其应用 |
| CN113260863A (zh) * | 2018-08-17 | 2021-08-13 | 豪夫迈·罗氏有限公司 | 用于心房纤颤的评价中的循环bmp10 (骨形态发生蛋白10) |
| JP7440042B2 (ja) * | 2018-10-29 | 2024-02-28 | 国立大学法人 東京医科歯科大学 | 間質性肺炎患者の呼吸機能の低下リスクに関する情報を取得する方法及びその利用 |
| JP7300642B2 (ja) * | 2019-06-14 | 2023-06-30 | 国立大学法人浜松医科大学 | 特発性肺線維症の予後予測方法 |
| CN110333358A (zh) * | 2019-06-24 | 2019-10-15 | 浙江大学 | 一种急性肺损伤小鼠肺脏全免疫细胞特征图谱的建立方法 |
| JP7614477B2 (ja) * | 2019-08-02 | 2025-01-16 | 国立医薬品食品衛生研究所長 | 間質性肺炎のタンパク質診断バイオマーカー |
| EP4117659A4 (en) * | 2020-03-13 | 2024-04-03 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
| CN115702351B (zh) * | 2020-04-17 | 2026-03-31 | 国立医药品食品卫生研究所长 | 重症药疹的蛋白质诊断生物标记物 |
| CN113607955A (zh) * | 2020-09-16 | 2021-11-05 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 新型冠状病毒肺炎分期与疗效评估细胞因子标志物及其应用 |
| CN113533750A (zh) * | 2020-10-22 | 2021-10-22 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 一种区分新型冠状病毒肺炎患者与健康者的系统 |
| US20250122293A1 (en) * | 2021-09-07 | 2025-04-17 | Fnct Biotech, Inc. | Csf3r as biomarker and therapeutic target for pulmonary fibrosis |
| WO2023081299A1 (en) * | 2021-11-05 | 2023-05-11 | Spiritus Therapeutics, Inc. | A purified enriched population exosomes derived from individuals with a chronic progressive lung disease for noninvasive detection, staging, and medical monitoring of disease progression |
| CN114563562A (zh) * | 2022-03-01 | 2022-05-31 | 复旦大学附属中山医院 | Prdx6联合铁离子检测在ards进程监测中的应用 |
| KR102907646B1 (ko) * | 2022-08-19 | 2026-01-05 | 울산대학교 산학협력단 | 특발성 폐섬유증 환자의 진단 및 경과예측용 호기 바이오마커 |
| CN119947728A (zh) * | 2022-09-28 | 2025-05-06 | 勃林格殷格翰国际有限公司 | 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途 |
| CN117025745B (zh) * | 2022-11-18 | 2024-02-23 | 中国医学科学院北京协和医院 | 分子标志物在诊断干燥综合征中的应用 |
| WO2026069490A1 (ja) * | 2024-09-25 | 2026-04-02 | 国立大学法人大阪大学 | 進行性肺線維症診断用バイオマーカー、該バイオマーカーを用いた進行性肺線維症の検査方法及びそれらの利用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US6019988A (en) | 1996-11-18 | 2000-02-01 | Bristol-Myers Squibb Company | Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage |
| JP4406206B2 (ja) * | 2001-04-24 | 2010-01-27 | バイエル コーポレーション | ヒトｔｉｍｐ−１抗体 |
| AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| JP2003238592A (ja) * | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| US20040219142A1 (en) | 2002-07-19 | 2004-11-04 | Abbott Laboratories S.A. | Treatment of skin and nail disorders using TNFalpha inhibitors |
| US7888485B2 (en) * | 2003-03-26 | 2011-02-15 | Georgetown University | Anti-pleiotrophin antibodies and methods of use thereof |
| US20060211752A1 (en) * | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| EP1626279B1 (en) * | 2004-08-12 | 2008-04-16 | Roche Diagnostics GmbH | Method for diagnosing liver fibrosis |
| CN101160528A (zh) * | 2005-02-14 | 2008-04-09 | 惠氏公司 | Il17-f在诊断和治疗气道炎症中的用途 |
| EP1757940A1 (en) * | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC |
| US20110129845A1 (en) * | 2007-01-29 | 2011-06-02 | Crc For Asthma And Airways Ltd. | Method of diagnosis |
| WO2009028158A1 (en) * | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| WO2010028274A1 (en) | 2008-09-05 | 2010-03-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation |
| US8568996B2 (en) * | 2008-10-21 | 2013-10-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | MMP activation peptide detection in biological samples |
| WO2010083392A2 (en) * | 2009-01-16 | 2010-07-22 | The Ohio State University Research Foundation | Ets-2 biomarkers for fibrotic diseases and uses thereof |
| EP2403880A1 (en) * | 2009-03-05 | 2012-01-11 | Tripath Imaging, Inc. | Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer |
| WO2010111625A1 (en) * | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| AU2010283997B2 (en) * | 2009-08-21 | 2015-04-09 | Gilead Biologics, Inc. | Methods and compositions for treatment of pulmonary fibrotic disorders |
| EP2496944A2 (en) * | 2009-11-05 | 2012-09-12 | Novartis AG | Biomarkers predictive of progression of fibrosis |
| WO2011091270A2 (en) * | 2010-01-21 | 2011-07-28 | The Regents Of The University Of Michigan | Biomarkers for lung disease monitoring |
| AU2012312515A1 (en) * | 2011-09-19 | 2014-03-13 | Genentech, Inc. | Combination treatments comprising c-met antagonists and B-raf antagonists |
| RU2015144149A (ru) | 2013-03-15 | 2017-04-21 | Интермьюн, Инк. | Протеомные маркеры илф |
-
2014
- 2014-03-14 RU RU2015144149A patent/RU2015144149A/ru unknown
- 2014-03-14 JP JP2016503081A patent/JP2016519763A/ja active Pending
- 2014-03-14 CN CN201480021359.5A patent/CN105122068A/zh active Pending
- 2014-03-14 HK HK16107519.9A patent/HK1219533A1/zh unknown
- 2014-03-14 MX MX2015012778A patent/MX2015012778A/es unknown
- 2014-03-14 US US14/213,970 patent/US9726677B2/en active Active - Reinstated
- 2014-03-14 EP EP14762377.1A patent/EP2972392A4/en not_active Withdrawn
- 2014-03-14 KR KR1020157027988A patent/KR20150130408A/ko not_active Withdrawn
- 2014-03-14 BR BR112015023699A patent/BR112015023699A2/pt not_active IP Right Cessation
- 2014-03-14 CA CA2901384A patent/CA2901384A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/029392 patent/WO2014144821A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014144821A1 (en) | 2014-09-18 |
| CN105122068A (zh) | 2015-12-02 |
| EP2972392A1 (en) | 2016-01-20 |
| US20140286929A1 (en) | 2014-09-25 |
| EP2972392A4 (en) | 2017-03-22 |
| HK1219533A1 (zh) | 2017-04-07 |
| MX2015012778A (es) | 2016-01-20 |
| BR112015023699A2 (pt) | 2017-07-18 |
| JP2016519763A (ja) | 2016-07-07 |
| CA2901384A1 (en) | 2014-09-18 |
| KR20150130408A (ko) | 2015-11-23 |
| US9726677B2 (en) | 2017-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015144149A (ru) | Протеомные маркеры илф | |
| JP2016519763A5 (https=) | ||
| Staudacher et al. | Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis | |
| Xaubet et al. | Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis | |
| Arron et al. | Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma | |
| McCombe et al. | Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis | |
| Arms et al. | Expression and function of CCL2/CCR2 in rat micturition reflexes and somatic sensitivity with urinary bladder inflammation | |
| JP6927212B2 (ja) | 軽度認知障害又はアルツハイマー型認知症の評価方法 | |
| HK1258292A1 (zh) | 使用il23途径生物标志物预测il23拮抗剂的临床应答 | |
| JP6755242B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP6755241B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP6755240B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| RU2015108959A (ru) | Способы прогнозирования риска развития гипертензии | |
| JP2017510622A (ja) | 筋萎縮を予測するバイオマーカー、方法および使用 | |
| BR112014019349A8 (pt) | Previsão do resultado nos pacientes com doença pulmonar obstrutiva crônica | |
| US20160178584A1 (en) | Methods for diagnosing and assessing kidney disease | |
| JP2015500988A (ja) | 肺障害のバイオマーカーとしてのｌｔｂｐ２ | |
| AU2021251382B2 (en) | Pro-adrenomedullin for prognosing disease progression in severe acute respiratory syndrome (SARS) | |
| JP2024023615A (ja) | 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのｐｒｏ－ａｄｍ | |
| Stefaniak et al. | Macrophage migration inhibitory factor as a potential predictor for requirement of renal replacement therapy after orthotopic liver transplantation | |
| US8309299B2 (en) | Combination therapy and method for assessing resistance to treatment | |
| RU2016147122A (ru) | Применение серелаксина для снижения gdf-15 | |
| RU2019144031A (ru) | Способ диагностики или мониторинга функции почек или диагностики дисфункции почек | |
| JP7258860B2 (ja) | 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ | |
| JP2015503106A5 (https=) |